logo-loader
viewCello Health PLC

Notice of Full Year Results

/**/ h1{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:18.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Times New Roman","serif";font-weight:bold;}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;font-size:14.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:10.5pt;font-family:"Times","serif";text-transform:uppercase;font-weight:normal;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bz{size:595.3pt 841.9pt;margin:53.85pt 72.0pt 36.0pt 36.85pt;}div.bz{}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; margin-left: 1.0cm; text-autospace: none; vertical-align: baseline}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; margin-left: 1.0cm; text-align: center; text-autospace: none; vertical-align: baseline}p.cw{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left: 1.0cm; text-align: center; text-autospace: none; vertical-align: baseline}p.cx{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left:1.0cm;text-autospace:none;vertical-align: baseline}span.cp{font-size:8.0pt}p.cy{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left:1.0cm;text-align:justify;text-autospace: none;vertical-align:baseline}p.cz{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; text-autospace: none; vertical-align: baseline}p.da{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 8.0pt; margin-left: 1.0cm; margin-right: 0cm; margin-top: 0cm; text-autospace: none; vertical-align: baseline} table.db{width:462.1pt;margin-left:-5.4pt;border-collapse:collapse}tr.cf{height:15.2pt}td.ci{width:286.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.2pt}p.dc{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-left:1.0cm}span.ck{color:black}td.cg{width:153.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.2pt}p.dd{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; margin-left: 1.0cm}span.cd{line-height:115%}p.de{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt; margin-left:1.0cm;line-height:115%;text-autospace:none;vertical-align:baseline}p.df{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Tahoma","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 10.0pt} span.cb{font-size:12.0pt;line-height:115%;color:black;border:none} /**/
RNS Number : 3033P
Cello Health PLC
07 February 2019
 

7 February 2019                                                                       

 

 

 

Cello Health plc

("Cello" or the "Group")

 

Notice of Full Year Results

 

 

Cello Health plc (AIM: CLL), the healthcare-led advisory group, expects to announce its preliminary results for the year ended 31 December 2018 on Thursday 21 March 2019.

 

A meeting for analysts will be held at 10.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further details please contact Buchanan on 020 7466 5000 or email [email protected].

 

 

 

Enquiries:

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive


Mark Bentley, Group Finance Director




Cenkos Securities (Nominated adviser and broker)

020 7397 8900

Mark Connelly


Harry Hargreaves




Buchanan

020 7466 5000

Mark Court


Jamie Hooper


Sophie Wills


 

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORLLFLDFLIRIIA

Quick facts: Cello Health PLC

Price: 126.255

Market: AIM
Market Cap: £134 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

1 month ago

RNS

Holding(s) in Company

1 week, 4 days ago

Total Voting Rights

1 week, 4 days ago

Disposal

2 weeks, 2 days ago

Interim Results

1 month ago

Acquisition of ISS

on 16/8/19